Mazyar Shadman, MD, MPH, on MB-106's Potential in Follicular Lymphoma

Video

The associate professor at Fred Hutch Cancer Center discussed data presented at the EHA 2022 Congress.

"We have not seen any grade 3 or 4 CRS and we haven't seen neurotoxicity at any grade for follicular lymphoma... It’s important to keep in mind, when we discuss different options with patients, especially in low grade lymphomas, the threshold for accepting toxicity may be different given the competitive landscape and different treatments that we have.”

MB-106, Mustang Bio’s CD20-targeted chimeric antigen receptor (CAR) T-cell therapy, demonstrated efficacy in the follicular lymphoma (FL) cohort of a phase 1/2 trial (NCT03277729). Findings from the cohort were presented at the European Hematology Association (EHA) 2022 Congress, June 9-12, held both virtually and in Vienna, Austria, by Mazyar Shadman, MD, MPH, associate professor, clinical research division, Fred Hutchinson Cancer Center, where the trial was conducted.

The trial has treated 18 patients in the FL cohort. All patients, except for the first of each dose cohort, were infused in the outpatient setting. Overall response rate (ORR) was 94% (n = 17) and complete response (CR) rate was 78% (n = 14). Three patients (17%) had a partial response and 1 (5%) experienced disease progression. No cases of grade 3 or above cytokine release syndrome were observed and there was no neurotoxicity observed.

CGTLive spoke with Shadman to learn more about the findings from the FL cohort. He discussed the positive efficacy and safety data and the next, multicenter trial of MB-106 that is now enrolling.

REFERENCE
Shadman M, Yeung C, Redman M, et al. Efficacy and safety of a third generation CD20 CART (MB-106) for treatment of relapsed/refractory follicular lymphoma (FL). Presented at: EHA 2022 Congress, June 9-12, Vienna, Austria and virtually. Abstract #S207.
Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Related Content
© 2025 MJH Life Sciences

All rights reserved.